SUVALENT
DEAD

Serial Number

90716777

Owner

SUVALENT THERAPEUTICS, INC.

Attorney

Holly Pranger

Filing Date

May 17, 2021

Add to watchlist:

No watchlists yet
View on USPTO

SUVALENT Trademark

Serial Number: 90716777

SUVALENT is a trademark filed by SUVALENT THERAPEUTICS, INC. on May 17, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

SUVALENT THERAPEUTICS, INC. (2 trademarks)

2101 CORPORATE CENTER DRIVE, SUITE 200
NEWBURY PARK, CA 91320

Entity Type: 03

Trademark Details

Filing Date

May 17, 2021

Registration Date

Not Registered

Published for Opposition

March 1, 2022

Goods & Services

Pharmaceuticals and medicines for the prevention and treatment of cancer; pharmaceuticals and medicines for the identification and treatment of tumors; pharmaceuticals preparations in the form of capsules, tablets, and powders for the treatment of cancer; intravenous pharmaceuticals, namely, vials for intravenous administration sold filled with preparations for the treatment of cancer; biological preparations for the prevention and treatment of cancer; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in the for testing and treatment of cancer; medical diagnostic reagents; diagnostic biomarker reagents for medical purposes; pharmaceutical preparations in the nature of drug delivery agents that facilitate administration of other pharmaceutical preparations into the human body for enhanced treatment of cancer

Pharmaceutical research and development; research and development in the pharmaceutical and biotechnology fields; testing, inspection, research, or development of pharmaceutical preparations for the prevention and treatment of cancer; research and development of pharmaceuticals and medicines for the identification and treatment of tumors; development of pharmaceutical preparations and medicines; providing medical and scientific research information in the fields of pharmaceutical and biological preparations; development of new technology for others in the fields of pharmaceuticals, biotechnology, and medicine; testing of pharmaceuticals; laboratory research services relating to pharmaceuticals; conducting early evaluations in the field of new pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical drug development services; consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, and diagnostics; biological research and analysis; chemical research; medical research, namely, conducting clinical trials for others

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jul 12, 2024 MAB6
ABANDONMENT - NO USE STATEMENT FILED
May 27, 2024 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 27, 2023 EXRA
SOU EXTENSION 3 GRANTED
Oct 24, 2023 EX3G
SOU EXTENSION 3 FILED
Oct 24, 2023 EXT3
SOU TEAS EXTENSION RECEIVED
Oct 24, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 18, 2023 EXRA
SOU EXTENSION 2 GRANTED
Apr 14, 2023 EX2G
SOU EXTENSION 2 FILED
Apr 14, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Apr 14, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 8, 2022 EXRA
SOU EXTENSION 1 GRANTED
Oct 6, 2022 EX1G
SOU EXTENSION 1 FILED
Oct 6, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Oct 6, 2022 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 26, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 1, 2022 NPUB
PUBLISHED FOR OPPOSITION
Mar 1, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 9, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 26, 2022 CNSA
ASSIGNED TO EXAMINER
Jan 25, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 16, 2021 NWOS
NEW APPLICATION ENTERED
May 20, 2021 NWAP